- Symbol
- CLLS
- Venue
- NASDAQ GLOBAL MARKET
- Segment MIC
- XNMS
- ISIN
- US15117K1034
- Trading currency
- USD
XNMS:CLLS — listed on NASDAQ GLOBAL MARKET
Cellectis is a clinical-stage biotechnology company that develops cell and gene therapies using its proprietary gene editing platform, TALEN®. The company focuses on creating off-the-shelf Chimeric Antigen Receptor (CAR) T-cell therapies aimed at treating various cancers, particularly relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). Cellectis operates globally and collaborates with strategic partners to enhance its research and development efforts, leveraging a strong intellectual property portfolio that includes numerous patents.